Halo Therapeutics is a technology company.
Halo Therapeutics has raised $2.0M across 1 funding round.
Halo Therapeutics has raised $2.0M in total across 1 funding round.
Halo Therapeutics has raised $2.0M in total across 1 funding round.
Halo Therapeutics's investors include Elbow Beach Capital.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a San Diego-based biotechnology company specializing in enzyme platform technology for subcutaneous drug delivery and oncology therapies targeting the tumor microenvironment.[1][2][4] Its core product, the Enhanze platform using recombinant human hyaluronidase (rHuPH20), enables faster, less invasive administration of biologics, serving pharmaceutical partners like Roche, Pfizer, and Bristol Myers Squibb while addressing gaps in cancer, neurological disorders, and chronic disease treatments.[1][2] The company licenses Enhanze for drug delivery optimization and develops its own pipeline, including the investigational PEGPH20 for hyaluronan-high tumors like pancreatic and gastric cancers, with one FDA-approved product, Hylenex, for subcutaneous fluid administration.[1][2]
Note: A separate UK entity, HALO THERAPEUTICS LTD (incorporated 2020), focuses on biotechnology R&D but lacks public details on products or traction, suggesting it's distinct and early-stage.[3]
Halozyme Therapeutics was founded in 1998 and went public in 2004, building its foundation on proprietary rHuPH20 enzyme technology to degrade hyaluronic acid and improve drug absorption.[1] Early focus centered on this platform, leading to FDA approval of Hylenex in 2005 and expansion into Enhanze licensing deals with major biopharma firms.[1][2] Pivotal moments include clinical trials for PEGPH20 across solid tumors and partnerships that now drive most revenue (e.g., bulk rHuPH20 sales at 16.41% and 8.5% of total revenue).[1][2] Helen Torley has led as CEO since 2014, steering growth in drug delivery and oncology.[1]
Halozyme rides the biotech trend toward patient-centric drug delivery, shifting from burdensome IV infusions to convenient subcutaneous options amid rising biologics demand for cancer and chronic diseases.[2][4] Timing aligns with post-pandemic emphasis on home-based care and cost efficiencies, bolstered by market forces like aging populations and biologics market growth (projected to exceed $500B by 2025).[2] It influences the ecosystem by enabling partners' dose optimization and pipeline acceleration, filling gaps in tumor microenvironment therapies where HA accumulation hinders treatment penetration.[1]
Halozyme's partner-driven model positions it for steady revenue growth via Enhanze expansions and PEGPH20 trial readouts, potentially unlocking new oncology indications.[1][2][4] Trends like AI-optimized biologics and combo immunotherapies will amplify its platform, with influence growing through more licensing deals if subcutaneous adoption surges. Watch for 2025-2026 pipeline milestones and UK Halo Therapeutics' potential emergence, though Halozyme remains the established biotech leader transforming drug administration.[1][3]
Halo Therapeutics has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in May 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2023 | $2.0M Seed | Elbow Beach Capital |